Gene deletion of NF-κB p105 enhances neointima formation in a mouse model of carotid artery injury

Cardiovascular Drugs and Therapy

Volumn 20, Issue 2, 2006, Pages 103-111

  Ruusalepp, Arno ^a,c   Yan, Zhong Qun ^b   Carlsen, Harald ^a   Czibik, Gabor ^a   Hansson, Göran K ^b   Moskaug, Jan Øyvind ^a   Blomhoff, Rune ^a   Valen, Guro ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c TARTU UNIVERSITY HOSPITAL   (Estonia)

Author keywords

Arteries; Gene expression; Inflammation; Neointima formation; Restenosis

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN P105; INTERLEUKIN 1BETA; LUCIFERASE; NITRIC OXIDE SYNTHASE; PROTEIN SUBUNIT; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; ARTERY LIGATION; ARTICLE; CAROTID ARTERY INJURY; CONTROLLED STUDY; ENZYME ACTIVATION; GENE DELETION; GENE EXPRESSION; HEALING; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REPORTER GENE; WILD TYPE;

ANIMALS; CAROTID ARTERY INJURIES; DISEASE MODELS, ANIMAL; ELECTROPHORETIC MOBILITY SHIFT ASSAY; GENE DELETION; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-1; LUCIFERASES; MALE; MICE; MICE, KNOCKOUT; NF-KAPPA B; NF-KAPPA B P50 SUBUNIT; NITRIC OXIDE SYNTHASE TYPE II; POLYMERASE CHAIN REACTION; PROTEIN BINDING; RECOMBINANT FUSION PROTEINS; TUMOR NECROSIS FACTOR-ALPHA; TUNICA INTIMA; VASCULITIS;

EID: 33745014097     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10557-006-6755-7     Document Type: Article

References (33)

1. Bult H. Restenosis: A challenge for pharmacology. Trends Pharmacol Sci 2000;21:274-279.
2. De Meyer GR, Bult H. Mechanisms of neointima formation-lessons from experimental models. Vasc Med 1997;2:179-189.
3. Hansson GK, Geng YJ, Holm J, Hardhammar P, Wennmalm A, Jennische E. Arterial smooth muscle cells express nitric oxide synthase in response to endothelial injury. J Exp Med 1994;180:733-738
4. Hu Y, Cheng L, Hochleitner BW, Xu Q. Activation of mitogen-activated protein kinases (ERK/JNK) and AP-1 transcription factor in rat carotid arteries after balloon injury. Arterioscler Thromb Vasc Biol 1997;17:2808-2816.
5. Landry DB, Couper LL, Bryant SR, Lindner V. Activation of the NF- kappa B and I kappa B system in smooth muscle cells after rat arterial injury. Induction of vascular cell adhesion molecule-1 and monocyte chemoattractant protein-1. Am J Pathol 1997;151:1085-1095.
6. Liao DF, Monia B, Dean N, Berk BC. Protein kinase C-zeta mediates angiotensin II activation of ERK1/2 in vascular smooth muscle cells. J Biol Chem 1997;272:6146-6150.
7. Squadrito F, Deodato B, Bova A, et al. Crucial role of nuclear factor-κB in neointimal hyperplasia of the mouse carotid artery after interruption of blood flow. Atherosclerosis 2003;166:233-242.
8. Ialenti A, Ianaro A, Maffia P, et al. Role of nuclear factor-kappaB in a rat model of vascular injury. Naunyn Schmiedebergs Arch Pharmacol 2001;364:343-350.
9. Hayashi K, Takahata H, Kitagawa N, Kitange G, Kaminogo M, Shibata S. N-acetylcystein inhibited nuclear factor-kappaB expression and the intimal hyperplasia in rat carotid artery injury. NeUrol Res 2001;23:731-738.
10. Maffia P, Ianaro A, Pisano B, et al. Beneficial effects of caffeic acid phenethyl ester in a rat model of vascular injury. British J Pharmacol 2002;136:353-360.
11. Breuss JM, Cejna M, Bergmeister H, et al. Activation of nuclear factor-κB significantly contributes to lumen loss in a rabbit iliac artery balloon angioplasty model. Circulation. 2002;105:633-638.
12. Ghosh S, Gifford AM, Riviere LR, Tempst P, Nolan GP, Baltimore D. Cloning of the p50 DNA binding subunit of NF-kappaB: Homology to rel and dorsal. Cell 1990;62:1019-1029.
13. Ishikawa H, Claudio E, Dambach D, Raventos-Suarez C, Ryan C, Bravo R. Chronic inflammation and susceptibility to bacterial infections in mice lacking the polypeptide (p)105 precursor (NF-kappaB1) but expressing p50. J Exp Med. 1998 Apr 6;187(7):985-996.
14. Baldwin AS. Series introduction: the transcription factor NF-kappaB and human disease. J Clin Invest 2001;107:3-6.
15. Collins T, Cybulsky MI. NF-kappaB: Pivotal mediator or innocent bystander in atherogenesis? J Clin Invest 2001;107:255-264.
16. Cercek B, Yamashita M, Dimayuga P, et al. Nuclear factor-κB activity and arterial response to balloon injury. Atherosclerosis 1997;131:59-66.
17. Sirsjö A, Löfving A, Hansson GK, Wågsäter D, Tokuno S, Valen G. Deficiency of nitric oxide synthase 2 results in increased neointima formation in a mouse model of vascular injury. J Cardiovasc Pharmacol 2003;41:897-902.
18. Jeremy JY, Rowe D, Emsley AM, Newby AC. Nitric oxide and the proliferation of vascular smooth muscle cells. Cardiovasc Res 1999; 43:580-594.
19. Newby AC, Zaltsman AB. Molecular mechanisms in intimal hyperplasia. J Pathol 2000;190:300-309.
20. Klein S, de Fougerolles AR, Blaikie P, et al. Alpha 5 beta 1 integrin activates an NF-kappaB - dependent program of gene expression important for angiogenesis and inflammation. Mol Cell Biol 2002;22:5912-5922.
21. Francis DJ, Parish CR, McGarry M, et al. Blockade of vascular smooth muscle cell proliferation and intimal thickening after balloon injury by the sulphated oligosaccharide PI-88. Circ Res 2003;92:70-77
22. Post MJ, Laham RJ, Kuntz RE, Novicki D, Simons M. The effect of intracoronary fibroblast growth factor 2 on restenosis after primary angioplasty or stent placement in a pig model of atherosclerosis. Clin Cardiol 2002;25:271-278.
23. Sha WC, Liou HC, Tuomanen EI, Baltimore D. Targeted disruption of the p50 subunit of NF-kappaB leads to multifocal defects in immune responses. Cell 1995;80:321-330.
24. Carlsen H, Moskaug JO, Fromm SH, Blomhoff R. In vivo imaging of NF-kappaB activity. J Immunol 2002;168:1441-1446.
25. Carmeliet P, Moons L, Collen D. Mouse models of angiogenesis, arterial stenosis, atherosclerosis and hemostasis. Cardiovasc Res 1998;39:8-33.
26. Meiners S, Laule M, Rother W, et al. Ubiquitin-proteasome pathway as a new target for the prevention of restenosis. Circulation 2002;105:483-439.
27. Geng Y-J, Wu Q, Muszynski M, Hansson GK, Libby P. Apoptosis of vascular smooth muscle cells induced by in vitro simulation with interferon-α, tumor necrosis factor-α and interleukin-1β. Arterioscl Thromb Vasc Biol 1996;16:19-27.
28. Bourcier T, Sukhova G, Libby P. The nuclear factor-kappaB signalling pathway participates in dysregulation of vascular smooth muscle cells in vitro and in human atherosclerosis. J Biol Chem 1997;272:15817-15824.
29. Liou HC, Nolan GP, Ghosh S, Fuita T, Baltimore D. The NF-kappaB p50 precursor, p105, contains an internal I kappa B-like inhibitor that preferentially inhibits p50. The EMBO Journal 1992;11:3003-3009.
30. Lawrence T, Gilroy DW, Colville-Nash PR, Willoughby DA. Possible role of NF-kappaB in the resolution of inflammation. Nat Med 2001;7:1291-1297.
31. Lindner V, Reidy MA. Proliferation of smooth muscle cells after vascular injury is inhibited by an antibody against bFGF. Proc Nat Acad Sci USA 1991;88:3739-3743.
32. Hanna AK, Fox JC, Neschis DG, Safford SD, Swain JL, Golden MA. Antisense basic fibroblast growth factor gene transfer reduces neointimal thickening after arterial injury. J Vasc Surg 1997;25:320-325.
33. Kipshidze NN, Kim HS, Iversen P, et al. Intramural coronary delivery of advanced antisense oligonucleotides reduces neointimal formation in the porcine stent restenosis model. JACC 2002;39:1686-1691.